Market Research Report
Nociceptin Receptor - Pipeline Review, H2 2020
|Published by||Global Markets Direct||Product code||358352|
|Published||Content info||60 Pages
Delivery time: 1-2 business days
|Nociceptin Receptor - Pipeline Review, H2 2020|
|Published: October 30, 2020||Content info: 60 Pages||
According to the recently published report 'Nociceptin Receptor - Pipeline Review, H2 2020'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.
The report 'Nociceptin Receptor - Pipeline Review, H2 2020' outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 5, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones and Undisclosed which include indications Pain, Substance (Drug) Abuse, Dyskinesia, Overactive Bladder, Somatic Pain, Alcohol Addiction, Diabetic Neuropathic Pain, Drug Addiction, Fibromyalgia (Fibromyalgia Syndrome), Insomnia, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Low Back Pain, Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Post-Operative Pain, Post-Traumatic Stress Disorder (PTSD) and Unspecified.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.